Research fuels our mission to end cancer
Many of the greatest minds in cancer research are at MD Anderson. They're here because MD Anderson offers a unique environment that accelerates their ability to end cancer. They collaborate with other cancer experts – in different research areas and with the world's leading cancer doctors. Bright students and trainees contribute further to our dynamic research environment. Discoveries are fueled by vast research support and resources. Tomorrow's medicine is available to our patients first since we have the most cancer clinical trials in the world. These research efforts work in parallel to fight cancer through prevention, early diagnosis, effective therapies and scientific breakthroughs.
2020 CPRIT Awards
to individual investigators
for individual investigator research
for recruitment and prevention
MD Anderson was awarded more than $20
million by the Cancer Prevention and Research Institute of Texas
(CPRIT) in February. These funds, which account for 28% of the $78
million awarded in total, will be used to support cancer research,
clinical translation, prevention and recruitment efforts across Texas
Departments, Labs and Institutes
MD Anderson has many parts, including departments, labs and institutes, but the sum of those parts is ending cancer. MD Anderson's reach is comprehensive when it comes to eliminating cancer.
Our laboratories cover the full breadth of cancer research. They’re led by some of the leading scientists and physicians in the world.
Scientists from different disciplines come together to focus on a common area in our research institutes.
Meet our cancer researchers
MD Anderson faculty focus on a variety of research topics that contribute to our goal of ending cancer.
Moon Shots Program
Inspired by an unprecedented era of scientific discovery a generation ago, the Moon Shots Program® was launched by MD Anderson as an ambitious plan to make a giant leap in cancer research to benefit patients.Learn more about the Moon Shots Program
CAR NK-cell therapy
Powerhouse of the cell
Glioma cell movement
MD Anderson announces strategic collaboration with Denali Therapeutics to research and develop targeted therapies for neurodegenerative diseases
MD Anderson Cancer Center and Denali Therapeutics Inc. announced a strategic research collaboration to develop novel therapies for Alzheimer’s and other neurodegenerative diseases. Together, researchers from Denali and MD Anderson’s Neurodegeneration Consortium (NDC) will investigate four therapeutic targets with the goal of advancing product candidates into clinical testing to meet unmet patient need.
What is CAR T cell therapy?
Dr. William Wierda discusses how this therapy is used to treat cancer.